Among the HCC patients treated with sorafenib, the Overall Survival (OS) and disease free survival (DFS) of HCC patients with low RELN expression were significantly lower than those of patients with high RELN expression (p = 0.0036, Figure 3(a); p = 0.0036, Figure 3(b)), there were no significant differences in progression free survival (PFS) and recurrence free survival (RFS) between HCC patients with low and high RELN expression (p = 0.19, Figure 3(c); p = 0.32, Figure 3(d)). Here, RELN is linked to hepatocellular carcinoma.